Cargando…

Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting

BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhines, Allison S., Feldman, Marcus W., Bendavid, Eran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150186/ https://www.ncbi.nlm.nih.gov/pubmed/30096067 http://dx.doi.org/10.1097/QAD.0000000000001959

Ejemplares similares

Isoniazid for preventing tuberculosis in HIV‐infected children
por: Zunza, Moleen, et al.
Publicado: (2017)

Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use
por: Hahn, Judith A., et al.
Publicado: (2023)

Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting
por: Padmapriyadarsini, C., et al.
Publicado: (2020)

Isoniazid Preventive Therapy for Prevention of Tuberculosis among People Living with HIV in Ethiopia: A Systematic Review of Implementation and Impacts
por: Assefa, Dawit Getachew, et al.
Publicado: (2022)

Implementing an isoniazid preventive therapy program for people living with HIV in Thailand
por: Danyuttapolchai, Junya, et al.
Publicado: (2017)

Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa
por: Szakacs, Tom A, et al.
Publicado: (2006)

Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV
por: Vojnov, Lara, et al.
Publicado: (2022)

Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania
por: Hunter, Olivia F., et al.
Publicado: (2020)

Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
por: Kagujje, Mary, et al.
Publicado: (2019)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
por: Balcells, Maria Elvira, et al.
Publicado: (2006)

Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections
por: Bächle, Susanna M., et al.
Publicado: (2016)

Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study
por: Mindachew, Mesele, et al.
Publicado: (2014)

Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury
por: Wang, Chao, et al.
Publicado: (2016)

Correction to: Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania
por: Hunter, Olivia F., et al.
Publicado: (2020)

Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice
por: Kim, Boe-Hyun, et al.
Publicado: (2019)

Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries
por: Charles, M. Katherine, et al.
Publicado: (2016)

The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination
por: Jones, Christine E., et al.
Publicado: (2015)

Isoniazid preventive therapy in HIV-infected pregnant and postpartum women in high prevalence of tuberculosis countries: A protocol for systematic review
por: Wang, Xiaozhuan, et al.
Publicado: (2020)

Superoxide Dismutase Levels and Polymorphism (Ala16val) In Tuberculosis Patients with Diabetes Mellitus in Medan City
por: Sari, Mutiara Indah, et al.
Publicado: (2019)

HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity
por: Suzuki, Kazuo, et al.
Publicado: (2021)

Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation
por: Bhilare, Neha Vithal, et al.
Publicado: (2018)

Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study
por: Ayele, Henok Tadesse, et al.
Publicado: (2015)

Fadu head and neck squamous cell carcinoma induces hyperexcitability of primary sensory neurons in an in vitro coculture model
por: Uhelski, Megan L., et al.
Publicado: (2022)

The Correlation between Levels of Transforming Growth Factor-β with Pulmonary Fibrosis in Post Pulmonary Tuberculosis in Medan, North Sumatera – Indonesia
por: Christine, Tamara, et al.
Publicado: (2019)

Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatment
por: Svensson Akusjärvi, Sara, et al.
Publicado: (2023)

Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia
por: Mebratu, Wondwosen, et al.
Publicado: (2022)

The Gene Polymorphisms (-308G/A) and the Tumor Necrosis Factor-alpha Levels in Type 2 Diabetic Patients with and Without Tuberculosis Infection
por: Daulay, Milahayati, et al.
Publicado: (2019)

The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis
por: Geremew, Demeke, et al.
Publicado: (2019)

Beneficial Effect of Isoniazid Preventive Therapy and Antiretroviral Therapy on the Incidence of Tuberculosis in People Living with HIV in Ethiopia
por: Yirdaw, Kesetebirhan Delele, et al.
Publicado: (2014)

Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children
por: Luabeya, Kany Kany A., et al.
Publicado: (2015)

Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe
por: Nyathi, Saziso, et al.
Publicado: (2019)

Isoniazid Preventive Therapy for Tuberculosis in People Living with HIV: A Cross Sectional Study in Butebo, Uganda
por: Oonyu, Lawrence, et al.
Publicado: (2022)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

A community-based isoniazid preventive therapy for the prevention of childhood tuberculosis in Ethiopia
por: Datiko, D. G., et al.
Publicado: (2017)

Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative
por: Sekayi, Wycliff, et al.
Publicado: (2023)

Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients
por: Toure, A., et al.
Publicado: (2016)

Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation
por: Bull, Marta E., et al.
Publicado: (2018)

Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts
por: Sherman, Brad T., et al.
Publicado: (2021)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

CD4(+) T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection
por: Buggert, Marcus, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e2e73mflft8fr2i7qeg4e8jtm1